Charles River Laboratories International (CNSX:CRL) and Akumin (TSE:AKU) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Charles River Laboratories International and Akumin, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Charles River Laboratories International | 0 | 0 | 0 | 0 | N/A |
Akumin | 0 | 1 | 1 | 0 | 2.50 |
Akumin has a consensus target price of C$4.25, suggesting a potential upside of 8.70%.
Profitability
This table compares Charles River Laboratories International and Akumin's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Charles River Laboratories International | N/A | N/A | N/A |
Akumin | N/A | N/A | N/A |
Earnings and Valuation
This table compares Charles River Laboratories International and Akumin's top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Charles River Laboratories International | N/A | N/A | N/A | N/A | N/A |
Akumin | C$246.08 million | 1.10 | C$-25,263,475.00 | C($0.37) | -10.71 |
Charles River Laboratories International has higher earnings, but lower revenue than Akumin.
Summary
Akumin beats Charles River Laboratories International on 2 of the 2 factors compared between the two stocks.